Huakang Biomedical Holdings Company Limited

Symbol: 8622.HK




Market price today

  • -6.0380

    P/E Ratio

  • 0.0540

    PEG Ratio

  • 45.04M

    MRK Cap

  • 0.00%

    DIV Yield

Huakang Biomedical Holdings Company Limited (8622-HK) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Shuguang Zhang
Full-time employees:96
City:Wan Chai
Address:Effectual Building

Huakang Biomedical Holdings Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of in-vitro diagnostic (IVD) reagents in the People's Republic of China. It offers male and female fertility IVD, parasite antibody detection, and Epstein-Barr virus antibody detection reagents; auxiliary reproductive supplies and equipment; and healthcare products and supplements under the Nutronic brand to customers, as well as through online and offline platforms and channels. The company sells its products directly to hospitals and medical institutions, as well as to distributors. Huakang Biomedical Holdings Company Limited was founded in 1992 and is headquartered in Wan Chai, Hong Kong.

General Outlook

When we look at how much money they make before expenses, they keep 0.653% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.223%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.235%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.089% return, is a testament to Huakang Biomedical Holdings Company Limited's adeptness in optimizing resource deployment. Huakang Biomedical Holdings Company Limited's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.107%. Furthermore, the proficiency of Huakang Biomedical Holdings Company Limited in capital utilization is underscored by a remarkable -0.105% return on capital employed.

Liquidity Ratios

Analyzing 8622.HK liquidity ratios reveals its financial health of the firm. The current ratio of 408.03% gauges short-term asset coverage for liabilities. The quick ratio (325.43%) assesses immediate liquidity, while the cash ratio (251.49%) indicates cash reserves.

Current Ratio408.03%
Quick Ratio325.43%
Cash Ratio251.49%

Profitability Ratios

8622.HK profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -23.48% underscores its earnings before tax deductions. The effective tax rate stands at 8.34%, revealing its tax efficiency. The net income per EBT, 100.00%, and the EBT per EBIT, 105.17%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -22.32%, we grasp its operational profitability.

Pretax Profit Margin-23.48%
Effective Tax Rate8.34%
Net Income per EBT100.00%
EBT per EBIT105.17%
EBIT per Revenue-22.32%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 4.08, it details the span from stock purchase to revenue. The 3 days it takes to settle debts showcases its creditor relations. Meanwhile, a 3 cash conversion cycle and 254.35% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

Days of Sales Outstanding325
Days of Inventory Outstanding145
Operating Cycle288.67
Days of Payables Outstanding27
Cash Conversion Cycle261
Receivables Turnover2.54
Payables Turnover13.38
Inventory Turnover2.51
Fixed Asset Turnover2.53
Asset Turnover0.38

Cash Flow Ratios

The cash per share value, 0.08, showcases liquidity position.

Cash per Share0.08
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio0.01
Short Term Coverage Ratio0.02

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 6.16%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.08, we discern the balance between debt and equity financing. The long-term debt to capitalization, 2.25%, and total debt to capitalization, 7.31%, ratios shed light on its capital structure. An interest coverage of -211.46 indicates its ability to manage interest expenses.

Debt Ratio6.16%
Debt Equity Ratio0.08
Long Term Debt to Capitalization2.25%
Total Debt to Capitalization7.31%
Interest Coverage-211.46
Cash Flow to Debt Ratio0.01
Company Equity Multiplier1.28

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.06, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.01, reflects the portion of profit attributed to each share. The book value per share, 0.12, represents the net asset value distributed per share, while the tangible book value per share, 0.12, excludes intangible assets.

Revenue Per Share0.06
Net Income Per Share-0.01
Book Value Per Share0.12
Tangible Book Value Per Share0.12
Shareholders Equity Per Share0.12
Interest Debt Per Share0.01

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -2.77%, indicates top-line expansion, while the gross profit growth, -4.85%, reveals profitability trends. EBIT growth, -127.44%, and operating income growth, -127.44%, offer insights into operational profitability progression. The net income growth, -88.03%, showcases bottom-line expansion, and the EPS growth, -82.89%, measures the growth in earnings per share.

Revenue Growth-2.77%
Gross Profit Growth-4.85%
EBIT Growth-127.44%
Operating Income Growth-127.44%
Net Income Growth-88.03%
EPS Growth-82.89%
EPS Diluted Growth-82.89%
Weighted Average Shares Growth2.80%
Weighted Average Shares Diluted Growth2.80%
Operating Cash Flow Growth-100.00%
Free Cash Flow Growth-100.00%
10-Year Revenue Growth per Share21.73%
5-Year Revenue Growth per Share-36.99%
3-Year Revenue Growth per Share7.81%
10-Year Operating CF Growth per Share-100.00%
5-Year Operating CF Growth per Share-100.00%
3-Year Operating CF Growth per Share100.00%
10-Year Net Income Growth per Share-170.08%
5-Year Net Income Growth per Share-824.26%
3-Year Net Income Growth per Share52.18%
10-Year Shareholders Equity Growth per Share211.00%
5-Year Shareholders Equity Growth per Share-47.29%
3-Year Shareholders Equity Growth per Share-20.69%
Receivables Growth2.25%
Inventory Growth8.95%
Asset Growth-1.64%
Book Value per Share Growth-12.20%
Debt Growth758.21%
R&D Expense Growth2.82%
SGA Expenses Growth8.00%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 11,419,533.192, captures the company's total value, considering both debt and equity. The sales, general, and administrative to revenue ratio, 0.40, gauges operational efficiency, while the research and development to revenue, 10.37%, highlights investment in innovation.

Enterprise Value11,419,533.192
Sales General and Administrative to Revenue0.40
Research and Development to Revenue10.37%
Graham Number0.20
Return on Tangible Assets-8.85%
Graham Net Net0.07
Working Capital40,340,000
Tangible Asset Value51,019,000
Net Current Asset Value39,140,000
Average Receivables9,576,500
Average Payables733,500
Average Inventory3,255,500
Days Sales Outstanding144
Days Payables Outstanding27
Days of Inventory On Hand145

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.68, and the price to book ratio, 0.68, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.70, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 946.51, and price to operating cash flows, 791.53, gauge market valuation against cash flow metrics.

Price Book Value Ratio0.68
Price to Book Ratio0.68
Price to Sales Ratio1.70
Price Cash Flow Ratio791.53
Price Earnings to Growth Ratio0.05
Enterprise Value Multiple-13.98
Price Fair Value0.68
Price to Operating Cash Flow Ratio791.53
Price to Free Cash Flows Ratio946.51
Price to Tangible Book Ratio0.79
Enterprise Value to Sales0.46
Enterprise Value Over EBITDA-2.31
Earnings Yield-14.34%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Huakang Biomedical Holdings Company Limited (8622.HK) on the HKSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -6.038 in 2024.

What is the ticker symbol of Huakang Biomedical Holdings Company Limited stock?

The ticker symbol of Huakang Biomedical Holdings Company Limited stock is 8622.HK.

What is company IPO date?

IPO date of Huakang Biomedical Holdings Company Limited is 2018-12-13.

What is company current share price?

Current share price is 0.090 HKD.

What is stock market cap today?

The market cap of stock today is 45042480.000.

What is PEG ratio in 2024?

The current 0.054 is 0.054 in 2024.

What is the number of employees in 2024?

In 2024 the company has 96.